Seres Therapeutics (MCRB) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2024 value amounting to $139.8 million.
- Seres Therapeutics' Income towards Parent Company rose 214431.93% to $139.8 million in Q3 2024 from the same period last year, while for Jun 2025 it was $139.8 million, marking a year-over-year increase of 61261.64%. This contributed to the annual value of $125.9 million for FY2024, which is 6478.68% up from last year.
- Per Seres Therapeutics' latest filing, its Income towards Parent Company stood at $139.8 million for Q3 2024, which was up 214431.93% from -$6.7 million recorded in Q2 2024.
- Over the past 5 years, Seres Therapeutics' Income towards Parent Company peaked at $139.8 million during Q3 2024, and registered a low of -$71.5 million during Q1 2023.
- For the 5-year period, Seres Therapeutics' Income towards Parent Company averaged around -$13.1 million, with its median value being -$20.2 million (2020).
- Per our database at Business Quant, Seres Therapeutics' Income towards Parent Company crashed by 19726.9% in 2023 and then soared by 214431.93% in 2024.
- Quarter analysis of 5 years shows Seres Therapeutics' Income towards Parent Company stood at -$18.0 million in 2020, then plummeted by 175.35% to -$49.7 million in 2021, then surged by 95.58% to -$2.2 million in 2022, then crashed by 197.27% to -$6.5 million in 2023, then skyrocketed by 2240.73% to $139.8 million in 2024.
- Its last three reported values are $139.8 million in Q3 2024, -$6.7 million for Q2 2024, and -$7.2 million during Q1 2024.